Contraindicated. Coadministration of doravirine with a powerful CYP3A inducer might minimize doravirine plasma concentrations and/or effects. Likely for loss of virologic reaction and doable resistance to doravirine.pentobarbital will reduce the extent or result of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/